Location History:
- Essex, GB (2023)
- Lexington, MA (US) (2023)
Company Filing History:
Years Active: 2023
Title: Inventor Spotlight: Spencer Campbell from Essex, GB
Introduction
Spencer Campbell is an innovative inventor based in Essex, GB, recognized for his contributions to the field of biotechnology. With a total of two patents to his name, he is making significant strides in therapeutic development, particularly in the area of antibody applications.
Latest Patents
Among his latest patents are two significant advancements:
1. **Anti-TIGIT and Anti-CD96 Antibodies** - This patent discloses multispecific molecules that bind specifically to CD96 and/or TIGIT, including isolated antibodies that target human TIGIT. The invention encompasses pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids for encoding them, expression vectors, host cells for production, and methods for treating subjects using these innovations.
2. **Anti-CD73 Antibodies and Methods of Use Thereof** - This patent involves antibodies that specifically target CD73, providing antagonistic functions. Additionally, these antibodies can include TGFβ-binding or VEGF-binding moieties. The invention similarly includes pharmaceutical compositions, nucleic acids, expression vectors, host cells, and therapeutic methods using these antibodies.
Career Highlights
Spencer Campbell works at Agenus Inc., a leader in immunotherapy research and development. His role at the company allows him to push the boundaries of current medical treatments and innovate new approaches to tackling diseases.
Collaborations
In his professional journey, Spencer collaborates with notable colleagues such as Olga Ignatovich and Emmanuel Cyrille Pascal Briend. These collaborations enhance his work and contribute to a dynamic research environment.
Conclusion
Spencer Campbell exemplifies an inventive spirit in the biotechnology sector, with his patents representing noteworthy advancements in antibody therapies. As he continues to work at Agenus Inc., his future innovations are anticipated to contribute further to the landscape of medical treatment and biotechnology.